Franklin Resources Inc. Has $13.40 Million Stake in Kura Oncology, Inc. (NASDAQ:KURA)

Franklin Resources Inc. reduced its holdings in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 3.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,538,592 shares of the company's stock after selling 49,809 shares during the quarter. Franklin Resources Inc. owned approximately 1.98% of Kura Oncology worth $13,401,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Point72 DIFC Ltd acquired a new position in Kura Oncology in the third quarter worth $146,000. Harbor Advisors LLC bought a new position in shares of Kura Oncology in the fourth quarter valued at about $87,000. E Fund Management Co. Ltd. acquired a new position in Kura Oncology during the 4th quarter worth about $90,000. Corient Private Wealth LLC acquired a new position in Kura Oncology during the 4th quarter worth about $109,000. Finally, Teacher Retirement System of Texas grew its holdings in Kura Oncology by 19.9% during the 4th quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company's stock worth $120,000 after acquiring an additional 2,285 shares during the last quarter.

Insider Activity

In related news, SVP Thomas James Doyle sold 4,949 shares of the business's stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares of the company's stock, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the company's stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares of the company's stock, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock worth $92,307 in the last 90 days. Corporate insiders own 5.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. BTIG Research lowered shares of Kura Oncology from a "buy" rating to a "neutral" rating in a research report on Thursday, February 6th. Wedbush reiterated an "outperform" rating and issued a $36.00 price objective on shares of Kura Oncology in a research report on Tuesday. JMP Securities reissued a "market outperform" rating and issued a $28.00 target price on shares of Kura Oncology in a research note on Thursday, February 6th. Scotiabank cut their price target on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating on the stock in a research note on Wednesday, January 8th. Finally, UBS Group lowered their price objective on Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. Three research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $25.50.

Kura Oncology Trading Up 2.5 %

KURA traded up $0.14 during mid-day trading on Friday, hitting $5.77. The stock had a trading volume of 2,111,548 shares, compared to its average volume of 1,123,108. The stock's fifty day simple moving average is $7.36 and its 200-day simple moving average is $10.86. The firm has a market capitalization of $465.96 million, a price-to-earnings ratio of -2.44 and a beta of 0.83. Kura Oncology, Inc. has a 1-year low of $5.41 and a 1-year high of $23.48. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. As a group, research analysts forecast that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.